GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (STU:137) » Definitions » Cyclically Adjusted Book per Share

Aldeyra Therapeutics (STU:137) Cyclically Adjusted Book per Share : €2.52 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aldeyra Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Aldeyra Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was €1.756. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.52 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Aldeyra Therapeutics's average Cyclically Adjusted Book Growth Rate was 724.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-04), Aldeyra Therapeutics's current stock price is €3.533. Aldeyra Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €2.52. Aldeyra Therapeutics's Cyclically Adjusted PB Ratio of today is 1.40.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Aldeyra Therapeutics was 17.67. The lowest was 0.00. And the median was 0.00.


Aldeyra Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Aldeyra Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics Cyclically Adjusted Book per Share Chart

Aldeyra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.26 2.20

Aldeyra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.35 1.88 2.20 2.52

Competitive Comparison of Aldeyra Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Aldeyra Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's Cyclically Adjusted PB Ratio falls into.



Aldeyra Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aldeyra Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.756/131.7762*131.7762
=1.756

Current CPI (Mar. 2024) = 131.7762.

Aldeyra Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.298 100.560 1.701
201409 1.152 100.428 1.512
201412 0.916 99.070 1.218
201503 1.854 99.621 2.452
201506 2.892 100.684 3.785
201509 2.632 100.392 3.455
201512 2.351 99.792 3.105
201603 1.898 100.470 2.489
201606 2.106 101.688 2.729
201609 1.820 101.861 2.355
201612 1.632 101.863 2.111
201703 1.730 102.862 2.216
201706 1.371 103.349 1.748
201709 2.015 104.136 2.550
201712 1.749 104.011 2.216
201803 1.485 105.290 1.859
201806 1.519 106.317 1.883
201809 1.168 106.507 1.445
201812 2.901 105.998 3.607
201903 2.581 107.251 3.171
201906 2.208 108.070 2.692
201909 1.701 108.329 2.069
201912 1.510 108.420 1.835
202003 1.333 108.902 1.613
202006 1.421 108.767 1.722
202009 1.520 109.815 1.824
202012 1.265 109.897 1.517
202103 2.222 111.754 2.620
202106 3.344 114.631 3.844
202109 3.217 115.734 3.663
202112 3.135 117.630 3.512
202203 2.970 121.301 3.226
202206 2.824 125.017 2.977
202209 2.797 125.227 2.943
202212 2.434 125.222 2.561
202303 2.180 127.348 2.256
202306 2.039 128.729 2.087
202309 1.947 129.860 1.976
202312 1.856 129.419 1.890
202403 1.756 131.776 1.756

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Aldeyra Therapeutics  (STU:137) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aldeyra Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.533/2.52
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Aldeyra Therapeutics was 17.67. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Aldeyra Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aldeyra Therapeutics (STU:137) Business Description

Industry
Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics (STU:137) Headlines

No Headlines